Applied Therapeutics Says FDA Unable To Approve Govorestat NDA Due To Clinical Deficiencies; Expects To Submit An NDA Early In Q1 Of 2025
Applied Therapeutics Receives Complete Response Letter From U.S. FDA Regarding New Drug Application For Govorestat For Classic Galactosemia
TC BioPharm Plc Files For Mixed Shelf Of Up To $100M
Wednesday Ends With Index Decline | Wall Street Today
Titan Pharmaceuticals Gets Non-Compliance Notice From Nasdaq
12 Health Care Stocks Moving In Wednesday's Pre-Market Session